The use of reboxetine in attention deficit and hiperactivity disorder in children, associated to mental reterdation and epilepsy. Presenting two cases

Abstract

The attention deficit/hyperactivity disorder (ADHD) represents one of the most predominant clinical and mental health problems in children and adolescents due to the great incapacity it produces. The etiology is still unknown, and although traditionally it was associated to the dopaminergic system in these last years new information reveals the growing importance of the noradrenergic system. At this moment we use stimulants as the main treatment in attention deficit and hyperactivity disorder, although a big percentage of children and adolescents don´t respond or have major side effects. This is why we need to find new treatments in this field.Some authors have suggested the use of Reboxetine, which mainly works trough a noradrenergic mechanism, as an effective treatment.We present the cases of two girls with attention deficit and hyperactivity disorder plus mental retardation and epilepsy in which we used Reboxetine with good tolerance and a positive response in conduct and cognitive areas.We suggest this treatment as a useful option in children with a similar clinical pattern and we express the need to create future lines of investigation in this direction.